Immediate Versus Deferred Initiation of Antiretroviral Therapy in HIV Infected Adults With Acute Opportunistic Infections

Phase 4, randomised, open-label trial of emtricitabine + tenofovir disoproxil, lopinavir + ritonavir and stavudine in human immunodeficiency virus infection (HIV) and opportunistic infection (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Survival, recurrence of presenting OI/bacterial infection (BI) or incidence of new AIDS-defining events, and HIV-1 plasma viral load at 48 weeks. Started Mar 2003; status: completed.